Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Algernon Announces Enrollment of First Patient in 2b/3 Human

<< Previous

Bullboard Posts

Next >>

Comment by Zxeusson Aug 05, 2020 10:56pm

144 Views

Post# 31370572

RE:RE:RE:RE:RE:RE:Algernon Announces Enrollment of First Patient in 2b/3 Human

And it's not Placebo. No intervention: Control Arm (Standard of Care only)

Zxeuss wrote: It's not blinded. (Masking: None (Open Label)

https://clinicaltrials.gov/ct2/show/NCT04382924?term=algernon&draw=1&rank=1

Unicorn9000 wrote:

Justforfun10 wrote: I doubt any update until 1 or 2 weeks after COMPLETION of study. Completion of study will not take place until 2 weeks after the last patient is treated. I believe the study is double blind so patients and DOCTORS won't know who is getting placebo, 20 mg or 40 mg.